Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11089214 | PMC |
| http://dx.doi.org/10.3389/fphar.2024.1414373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.
Front Oncol
January 2025
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Background: Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.
Case Description: This report examines the efficacy and safety of sequential pre-treatment with the marine-derived alkaloid trabectedin followed by checkpoint inhibition using the anti-PD-1 antibody nivolumab in a 63-year-old male patient with unresectable retroperitoneal DDLPS. Treatment was initiated at the time of the seventh relapse as part of the NitraSarc phase 2 multicenter trial for inoperable soft tissue sarcoma conducted by the German Interdisciplinary Sarcoma Group (GISG-15, ).
Advanced clinical services in community pharmacies: training challenges and real-world applications - a focus on Greek-speaking countries.
J Pharm Policy Pract
January 2025
Pharmacy Programme, Department of Health Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.
Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk.
Subst Abuse Rehabil
January 2025
Department of Psychiatry, Texas Tech University Health Sciences, School of Medicine, Midland, TX, USA.
Potential of neutrophil-to-eosinophil ratio as a new prognostic tool for patients with advanced renal cell carcinoma receiving first-line immuno-oncology combinations.
BMJ Oncol
July 2024
Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancer.
BMJ Oncol
February 2024
NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!